Sihe Zhang | Medicine | Distinguished Scientist Award

Published on by Scientific World Research Awards

Distinguished Scientist Award

Sihe Zhang
Nankai University, China

Sihe Zhang
Affiliation Nankai University
Country China
Scopus ID 7409373738
Documents 55
Citations 1,269
h-index 16
Subject Area Medicine
Event Scientific World Research Awards
ORCID 0000-0002-8923-1993

The Distinguished Scientist Award recognizes the scholarly achievements of Sihe Zhang, Professor and Director at Nankai University School of Medicine. His research focuses on cancer biology, drug delivery systems, endocytosis, extracellular vesicles, antibody therapeutics, and translational medicine. Through sustained contributions to hepatocellular carcinoma and ovarian cancer research, he has developed innovative approaches that connect molecular mechanisms with therapeutic applications.[1]

Abstract

Sihe Zhang is a biomedical researcher whose work spans cancer biology, antibody engineering, cellular uptake mechanisms, extracellular vesicle biology, and targeted therapeutic delivery. His investigations have contributed to understanding macropinocytosis, endocytic recycling, tumor progression, and resistance mechanisms in hepatocellular and ovarian cancers. He has also participated in the development of innovative antibody-based therapies and nanomedicine strategies aimed at improving treatment specificity and efficacy. His publication portfolio demonstrates a sustained commitment to translational medical research and interdisciplinary collaboration, supporting advancements in cancer diagnosis, drug delivery, and precision medicine.[1][2]

Keywords

Cancer Biology; Drug Delivery; Endocytosis; Extracellular Vesicles; Antibody Therapeutics; Hepatocellular Carcinoma; Ovarian Cancer; Nanomedicine.

Introduction

Professor Zhang has held academic positions at Nankai University and previously at the Fourth Military Medical University. His career reflects long-term engagement with molecular medicine and cell biology, emphasizing mechanisms that influence cancer progression and treatment response.[1]

Research Profile

His research profile combines laboratory discovery with translational applications. Major themes include cellular trafficking, therapeutic antibodies, tumor microenvironment studies, and targeted delivery platforms designed to improve treatment outcomes in oncology.[1]

Research Contributions

Notable contributions include investigations into CD147-mediated signaling, extracellular vesicle uptake, macropinocytosis-driven drug resistance, and antibody-based cancer therapies. These studies have expanded understanding of tumor biology and therapeutic targeting strategies.[2][3]

Publications

His scholarly record includes 55 indexed publications. Representative works address hepatocellular carcinoma resistance mechanisms, extracellular vesicle biology, peptide delivery systems, anti-CD147 therapeutics, and nanobiotechnology-based treatment approaches.[2][4]

Research Impact

With 1,269 citations and an h-index of 16, his research has influenced studies in cancer therapeutics, molecular oncology, and biomedical engineering. The impact of his work is reflected through citations, collaborations, and peer-review activities across leading journals.[1]

Award Suitability

The breadth of Professor Zhang’s contributions, combined with sustained publication output and translational relevance, aligns with the objectives of the Scientific World Research Awards. His work demonstrates scientific rigor and practical relevance in medicine.[1]

Conclusion

Sihe Zhang has established a recognized research portfolio in cancer biology and therapeutic innovation. His scholarly achievements and ongoing contributions support recognition through the Distinguished Scientist Award.[1]

References

  1. ORCID. (2026). Sihe Zhang (0000-0002-8923-1993) Research Profile.https://orcid.org/0000-0002-8923-1993
  2. Qian, L., et al. (2025). The uptake of extracellular vesicles: Research progress in cancer drug resistance and beyond. Drug Resistance Updates.https://doi.org/10.1016/j.drup.2025.101209
  3. Qi, F.Z., et al. (2024). Hypoxia-activated ADCC-enhanced humanized anti-CD147 antibody. MedComm.https://doi.org/10.1002/mco2.512
  4. Sun, Z., et al. (2023). Cell-Penetrating Peptide-Based Delivery of Macromolecular Drugs. Biomedicines.https://doi.org/10.3390/biomedicines11071971
  5. Wang, B., et al. (2024). Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302. International Journal of Biological Sciences.https://doi.org/10.7150/ijbs.92211

Asterios Deligiannis | Medicine | Best Innovation Award

Published on by Scientific World Research Awards

Best Innovation Award

Asterios Deligiannis

Researcher Information
Affiliation Aristotle University of Thessaloniki
Country Greece
Scopus ID 7003501457
Documents 127
Citations 5,944
h-index 28
Subject Area Chemistry
Event Scientific World Research Awards
ORCID 0000-0001-7765-1897

Asterios Deligiannis is an academic affiliated with Aristotle University of Thessaloniki, Greece. His scholarly record demonstrates extensive research productivity, interdisciplinary collaboration, and sustained scientific contribution. According to available research metrics, he has produced 127 indexed publications, received 5,944 citations, and achieved an h-index of 28, reflecting broad academic visibility and influence across multiple research domains.[1][2]

Abstract

This article presents an overview of the academic achievements of Asterios Deligiannis. His research portfolio encompasses a substantial body of scholarly work, international collaborations, and contributions to scientific knowledge. Available publication metrics indicate 127 indexed documents, 5,944 citations, and an h-index of 28, reflecting sustained research productivity and scholarly influence.[1] His academic activities include participation in international research initiatives, professional organizations, and peer-reviewed publications. These accomplishments demonstrate innovation, research leadership, and measurable scientific impact, supporting consideration for recognition through the Best Innovation Award within an international academic framework.[2]

Keywords

Innovation, Chemistry, Scientific Research, Academic Impact, Research Excellence, Scholarly Contributions.

Introduction

Research innovation is commonly assessed through scientific productivity, influence, and contributions to knowledge development. Academic recognition programs frequently consider publication records, citation performance, and interdisciplinary engagement when evaluating researchers for distinguished awards.[1]

Research Profile

Deligiannis is affiliated with Aristotle University of Thessaloniki and maintains an active ORCID record. His professional activities include academic leadership, international memberships, and participation in collaborative research programs.[2]

Research Contributions

His scholarly contributions span cardiovascular health, exercise-related investigations, rehabilitation studies, and interdisciplinary scientific research. Numerous peer-reviewed publications demonstrate long-term engagement in advancing evidence-based knowledge and innovation.[3]

Publications

The researcher has authored 127 indexed publications and contributed to a broad collection of scientific articles published in international journals. His publication record reflects sustained scholarly activity and extensive collaboration across research communities.[1]

Research Impact

Research influence is demonstrated through 5,944 citations and an h-index of 28. These indicators suggest significant academic visibility and continuing relevance of his publications within scientific literature and research networks.[1]

Award Suitability

The combination of research productivity, scholarly impact, international engagement, and documented scientific contributions supports consideration for the Best Innovation Award. His profile reflects characteristics commonly associated with academic distinction and innovation-oriented recognition.[1]

Conclusion

Asterios Deligiannis has established a substantial academic record characterized by impactful publications, collaborative research activities, and measurable scholarly influence. These achievements provide a strong foundation for recognition within international research award programs.

References

  1. Elsevier. (n.d.). Scopus Author Details: Asterios Deligiannis, Author ID 7003501457. Scopus.

    https://www.scopus.com/authid/detail.uri?authorId=7003501457

  2. ORCID. (2026). Asterios Deligiannis ORCID Record.

    https://orcid.org/0000-0001-7765-1897

  3. Deligiannis, A., et al. (2025). Investigating the Role of Exercise in Improving Bone Health Among Elderly Women with Osteopenia.

    https://doi.org/10.3390/jfmk10040451

  4. Deligiannis, A., et al. (2025). Advanced Stress Echocardiography with Cardiopulmonary Exercise Testing After Myocardial Infarction.

    https://doi.org/10.3390/jfmk10040393

  5. Scientific World Research Awards. (n.d.). Official Award Information Portal.

    https://scientificworld.net/

Yoshiya Tanaka | Medicine | Innovative Research Award

Published on by Scientific World Research Awards

Innovative Research Award

Yoshiya Tanaka

Yoshiya Tanaka
Affiliation Hospital of University of Occupational and Environmental Health
Country Japan
Scopus ID 56328279400
Documents 1,326
Citations 50,831
h-index 99
Subject Area Medicine
Event Scientific World Research Awards

Yoshiya Tanaka, Hospital of University of Occupational and Environmental Health, Japan, is recognized for substantial contributions to rheumatology, immunology, and autoimmune disease research. His scholarly output, clinical investigations, and leadership in international collaborations have supported advancements in evidence-based medical practice and therapeutic development.[1]

Abstract

The Innovative Research Award recognizes researchers whose work demonstrates sustained scientific excellence and measurable impact. Yoshiya Tanaka has contributed extensively to rheumatology and clinical immunology through studies on autoimmune diseases, inflammatory mechanisms, biologic therapies, and targeted treatments. His research has informed clinical guidelines, improved disease classification systems, and supported the development of therapeutic strategies for conditions such as systemic lupus erythematosus, rheumatoid arthritis, and IgG4-related disease. With a substantial publication record and broad international collaboration, his work has influenced both academic research and patient care, reflecting the objectives of the Scientific World Research Awards.[1][2]

Keywords

Rheumatology, Clinical Immunology, Autoimmune Diseases, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Biologic Therapy, Translational Medicine.

Introduction

Modern rheumatology depends on interdisciplinary research linking immunology, molecular biology, and clinical practice. Yoshiya Tanaka has participated in investigations that enhanced understanding of inflammatory pathways and treatment approaches for immune-mediated diseases.[3]

Research Profile

As Professor and Chairman in rheumatology and clinical immunology, Tanaka has developed a research portfolio focused on disease mechanisms, therapeutic innovation, and clinical trial leadership. His scholarly record reflects long-term engagement with translational medicine and global collaboration.[1]

Research Contributions

Key contributions include studies supporting lupus classification criteria, IgG4-related disease frameworks, Janus kinase inhibitor development, and biologic treatment evaluation. These efforts have contributed to improved disease assessment and therapeutic decision-making.[2][4]

Publications

  • 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus.
  • Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
  • Janus Kinase-Targeting Therapies in Rheumatology.

Research Impact

The researcher’s publications have received extensive citations, demonstrating influence across clinical medicine and immunology. Findings from collaborative studies have informed guidelines, therapeutic development, and evidence-based healthcare practices internationally.[1][5]

Award Suitability

The breadth of scientific output, citation performance, clinical relevance, and leadership in collaborative research aligns with the objectives of the Innovative Research Award. His contributions demonstrate sustained scholarly influence and practical significance in medicine.

Conclusion

Yoshiya Tanaka’s career reflects a consistent commitment to advancing knowledge in rheumatology and autoimmune disease research. His achievements support recognition within international scientific award programs and academic communities.

References

  1. Elsevier. (n.d.). Scopus author details: Yoshiya Tanaka, Author ID 56328279400. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56328279400
  2. Aringer, M., et al. (2019). 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus.
    DOI: https://doi.org/10.1002/art.40930
  3. Tanaka, Y., Adams, D.H., & Shaw, S. (1993). T-cell Adhesion Induced by Proteoglycan-Immobilized Cytokine MIP-1β.
    DOI: https://doi.org/10.1038/361079a0
  4. Tanaka, Y., Luo, Y., O’Shea, J.J., & Nakayamada, S. (2022). Janus Kinase-Targeting Therapies in Rheumatology.
    DOI: https://doi.org/10.1038/s41584-021-00726-8
  5. Google Scholar. (2026). Yoshiya Tanaka Citation Profile.
    https://scholar.google.com/citations?user=t_hAg7QAAAAJ&hl=en